|
Treatment
> Bevacizumab
/ Temozolomide
Clinical Trials
|
|
Journal of Clinical Oncology, 2006 ASCO Annual Meeting Proceedings
(Post-Meeting Edition).
Vol 24, No 18S (June 20 Supplement), 2006: 11522
|
|
|
|
|
Meeting Abstract |
|
|
|
Combination of bevacizumab, a
monoclonal antibody to vascular endothelial growth factor (VEGF), and
temozolomide: Study of cases
J. Kirkpatrick,
A. Desjardins, J. J. Vredenburgh, J.
A. Quinn, J. N. Rich, S. Sathornsumetee,
S. Gururangan, A. H. Friedman, H. S.
Friedman and D.
A. Reardon
Duke University Medical Center,
Durham, NC
|
|
|
|
|
Background.
The prognosis for glioblastoma multiforme remains poor.
Survival is generally limited to less than
1 year.
Currently available standard
treatments have not allowed, thus far, to prolong survival
significantly.
Response rates observed in clinical trials
evaluating glioblastoma multiforme are usually less than 20%.
Knowing that malignant gliomas have high
concentrations of VEGF receptors, and the higher the VEGF
receptor concentration, the worse the prognosis, we decided
to evaluate the efficacy of bevacizumab in malignant brain
tumor patients.
Bevacizumab is a humanized IgG1
monoclonal antibody to VEGF, which is synergistic with
chemotherapy for most malignancies.
We performed a phase II study
combining bevacizumab with irinotecan for patient with malignant
gliomas and observed an unprecedented response rate of
63%.
Methods. Building of
those results, we decided to treat a number of our patients
with voluminous unresectable disease with bevacizumab and
temozolomide as an upfront regimen.
Temozolomide is an oral
methylating agent known effective for primary malignant brain
tumor patients.
A phase III trial, first presented at
the ASCO meeting of 2003, demonstrated the efficacy of
temozolomide for newly diagnosed glioblastoma multiforme
patients, establishing temozolomide as the new standard of
care.
Given the known results with
temozolomide as monotherapy and the combination of bevacizumab with
irinotecan, we treated patients with temozolomide and bevacizumab
upfront.
Results. With this new
combination, some patients demonstrated dramatic
improvement clinically and radiographically.
The combination has been well
tolerated thus far, with no incidence of hemorrhage or
arterial thrombosis observed.
Conclusions. Results will
be updated at the time of presentation.
|
|
|
|
|
© 2006 American Society of Clinical
Oncology
|
|
|
Meeting
Abstract |
News
|
|
|
|
